Page last updated: 2024-09-03

vadimezan and Melanoma

vadimezan has been researched along with Melanoma in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Banciu, M; Licarete, E; Luput, L; Mot, AC; Patras, L; Porfire, A; Rakosy-Tican, E; Rauca, VF; Sesarman, A; Toma, VA1
Cichoń, T; Jarosz-Biej, M; Kułach, N; Pilny, E; Poczkaj, A; Smolarczyk, R; Szala, S1
Chen, CJ; Ching, LM; Dunbar, PR; Henare, K; Print, C; Thomsen, L; Tijono, S; Wang, L; Wang, LC; Winkler, S1
Baguley, BC; Kelland, LR; Marshall, ES; Zhao, L1
Baguley, BC; Cao, Z; Ching, LM; Joseph, WR; Marshall, ES; Mountjoy, KG1
Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR1

Other Studies

6 other study(ies) available for vadimezan and Melanoma

ArticleYear
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
    Scientific reports, 2021, 11-11, Volume: 11, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Liposomes; Macrophages; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Skin Neoplasms; Tumor Microenvironment; Xanthones

2021
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
    Scientific reports, 2018, 05-09, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Digoxin; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Melanoma; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Xanthones; Xenograft Model Antitumor Assays

2018
Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Gene Regulatory Networks; Homeodomain Proteins; Humans; Leukocytes; Macrophages; Melanoma; Mice; Mice, Knockout; Mice, Nude; Oligonucleotide Array Sequence Analysis; Stromal Cells; Transcription, Genetic; Tumor Burden; Up-Regulation; Xanthones; Xenograft Model Antitumor Assays

2012
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Investigational new drugs, 2007, Volume: 25, Issue:3

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Line, Tumor; Cell Proliferation; Cell Shape; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Laminin; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proteoglycans; Pyridines; RNA, Messenger; Xanthones; Xenograft Model Antitumor Assays

2007
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Cancer research, 1999, Feb-01, Volume: 59, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Lipopolysaccharides; Liver; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Spleen; Stimulation, Chemical; Transplantation, Heterologous; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1999
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
    Cancer research, 2000, Aug-15, Volume: 60, Issue:16

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones

2000